Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors

PURPOSE: We conducted a first-in-man (to our knowledge) phase I study to determine the dose-limiting toxicities (DLTs), characterize the pharmacokinetic profile, and document any antitumor activity of ON 01910.Na, a new chemical entity that arrests cancer cells in G(2)/M by modulating mitotic regula...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Jimeno, Antonio, Li, Jing, Messersmith, Wells A., Laheru, Daniel, Rudek, Michelle A., Maniar, Manoj, Hidalgo, Manuel, Baker, Sharyn D., Donehower, Ross C.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2008
Matèries:
Phase I and Clinical Pharmacology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4824307/
https://ncbi.nlm.nih.gov/pubmed/18955447
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.17.9788
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars